Preventive effect of salicylate and pyridoxamine on diabetic nephropathy

Journal of Diabetes Research

Volumn 2016, Issue , 2016, Pages

  Abouzed, Tarek Kamal ^a,b   Munesue, Seiichi ^a   Harashima, Ai ^a   Masuo, Yusuke ^a   Kato, Yukio ^a   Khailo, Khaled ^b   Yamamoto, Hiroshi ^a   Yamamoto, Yasuhiko ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b Kafrelsheikh University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DRINKING WATER; GLUCOSE; GLYOXALASE; GLYOXALASE 1; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN DETEMIR; PYRIDOXAMINE; SALICYLIC ACID; UNCLASSIFIED DRUG; GLUCOSE BLOOD LEVEL; LONG ACTING INSULIN; NONSTEROID ANTIINFLAMMATORY AGENT; SALICYLIC ACID DERIVATIVE;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; GENE EXPRESSION; GENE OVEREXPRESSION; GLOMERULOSCLEROSIS; GLUCOSE BLOOD LEVEL; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; UPREGULATION; ANALYSIS; ANIMAL; BLOOD; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUG EFFECTS; FLOW CYTOMETRY; HEMODYNAMICS; INFLAMMATION; KIDNEY; METABOLISM;

ALBUMINURIA; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD GLUCOSE; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FLOW CYTOMETRY; HEMODYNAMICS; INFLAMMATION; INSULIN, LONG-ACTING; INSULIN-SECRETING CELLS; KIDNEY; MACROPHAGES; MALE; MICE; NITRIC OXIDE SYNTHASE TYPE II; PYRIDOXAMINE; SALICYLATES;

EID: 85006284999     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2016/1786789     Document Type: Article

References (30)

1. J. L. Gross, M. J. de Azevedo, S. P. Silveiro, L. H. Canani, M. L. Caramori, and T. Zelmanovitz, Diabetic nephropathy: diagnosis, prevention, and treatment, Diabetes Care, vol. 28, no. 1, pp. 164-176, 2005.
2. L. Gnudi, S. M. Thomas, and G. Viberti, Mechanical forces in diabetic kidney disease: a trigger for impaired glucose metabolism, Journal of theAmerican Society of Nephrology, vol. 18, no. 8, pp. 2226-2232, 2007.
3. H. Abe, T. Matsubara, H. Arai, and T. Doi, Role of Smad1 in diabetic nephropathy: molecular mechanisms and implications as a diagnostic marker, Histology and Histopathology, vol. 26, no. 4, pp. 531-541, 2011.
4. M. Brownlee, Biochemistry and molecular cell biology of diabetic complications, Nature, vol. 414, no. 6865, pp. 813-820, 2001.
5. J. M. Forbes, M. E. Cooper, M. D. Oldfield, and M. C. Thomas, Role of advanced glycation end products in diabetic nephropathy, Journal of theAmericanSociety ofNephrology, vol. 14, no. 3, pp. S254-S258, 2003.
6. H. Yamamoto, T. Watanabe, Y. Yamamoto, et al., RAGE in diabetic nephropathy, Current Molecular Medicine, vol. 7, no. 8, pp. 752-757, 2007.
7. Y. Yamamoto, and H. Yamamoto, Receptor for advanced glycation end-products-mediated inflammation and diabetic vascular complications, Journal of Diabetes Investigation, vol. 2, no. 3, pp. 155-157, 2011.
8. Y. Yamamoto, I. Kato, T. Doi, et al., Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice, Journal of Clinical Investigation, vol. 108, no. 2, pp. 261-268, 2001.
9. K.-M. Myint, Y. Yamamoto, T. Doi, et al., RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin, Diabetes, vol. 55, no. 9, pp. 2510-2522, 2006.
10. Y. Yamamoto, and H. Yamamoto, Controlling the receptor for advanced glycation end-products to conquer diabetic vascular complications, Journal ofDiabetes Investigation, vol. 3, no. 2, pp. 107-114, 2012.
11. M. T. T. Win, Y. Yamamoto, S. Munesue, et al., Regulation of RAGE for attenuating progression of diabetic vascular complications, Experimental Diabetes Research, vol. 2012, Article ID 894605, 8 pages, 2012.
12. A. A. Booth, R. G. Khalifah, and B. G. Hudson, Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine, Biochemical and Biophysical Research Communications, vol. 220, no. 1, pp. 113-119, 1996.
13. T. P. Degenhardt, N. L. Alderson, D. D. Arrington, et al., Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat, Kidney International, vol. 61, no. 3, pp. 939-950, 2002.
14. N. L. Alderson, M. E. Chachich, N. N. Youssef, et al., The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats, Kidney International, vol. 63, no. 6, pp. 2123-2133, 2003.
15. M.-J. Yin, Y. Yamamoto, and R. B. Gaynor, The antiinflammatory agents aspirin and salicylate inhibit the activity of IB kinase, Nature, vol. 396, no. 6706, pp. 77-80, 1998.
16. A. B. Goldfine, V. Fonseca, K. A. Jablonski, L. Pyle, M. A. Staten, and S. E. Shoelson, The effects of salsalate on glycemic control in patients with type 2 diabetes: a rand omized trial, Annals of Internal Medicine, vol. 152, no. 6, pp. 346-357, 2010.
17. A. B. Goldfine, V. Fonseca, K. A. Jablonski, et al., Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team. Salicylate (salsalate) in patients with type 2 diabetes: a rand omized trial, Annals of Internal Medicine, vol. 159, no. 1, pp. 1-12, 2013.
18. J. I. Barzilay, K. A. Jablonski, V. Fonseca, et al., The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes, Diabetes Care, vol. 37, no. 4, pp. 1083-1091, 2014.
19. T. Takamura, I. Kato, N. Kimura, et al., Transgenic mice overexpressing type 2 nitric-oxide synthase in pancreatic cells develop insulin-dependent diabetes without insulitis, Journal of Biological Chemistry, vol. 273, no. 5, pp. 2493-2496, 1998.
20. S. Ohashi, H. Abe, T. Takahashi, et al., Advanced glycation end products increase collagen-specific chaperone protein in mouse diabetic nephropathy,The Journal of Biological Chemistry, vol. 279, no. 19, pp. 19816-19823, 2004.
21. P. Patrignani, S. Tacconelli, E. Piazuelo, et al., Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action, Journal ofThrombosis and Haemostasis, vol. 12, no. 8, pp. 1320-1330, 2014.
22. M. Yuan, N. Konstantopoulos, J. Lee, et al., Reversal of obesityand diet-induced insulin resistance with salicylates or targeted disruption of Ikk, Science, vol. 293, no. 5535, pp. 1673-1677, 2001.
23. S. E. Shoelson, J. Lee, and M. Yuan, Inflammation and the IKKB/NF-B axis in obesity- And diet-induced insulin resistance, International Journal ofObesity, vol. 27, pp. S49-S52, 2003.
24. Y. T. Kwak, J. Guo, J. Shen, and R. B. Gaynor, Analysis of domains in the IKK and IKK proteins that regulate their kinase activity, Journal of Biological Chemistry, vol. 275, no. 19, pp. 14752-14759, 2000.
25. E. C. Abraham, M. S. Swamy, and R. E. Perry, Nonenzymatic glycosylation (glycation) of lens crystallins in diabetes and aging, Progress in Clinical and Biological Research, vol. 304, pp. 123-139, 1989.
26. D. Cai, M. Yuan, D. F. Frantz, et al., Local and systemic insulin resistance resulting from hepatic activation of IKK-And NF-B, Nature Medicine, vol. 11, no. 2, pp. 183-190, 2005.
27. A. B. Goldfine, R. Silver, W. Aldhahi, et al., Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes, Clinical and Translational Science, vol. 1, no. 1, pp. 36-43, 2008.
28. M.-S. Kim, Y. Yamamoto, K. Kim, et al., Regulation of dietinduced adipose tissue and systemic inflammation by salicylates and Pioglitazone, PLoS ONE, vol. 8, no. 12, Article ID e82847, 2013.
29. P. A. Voziyan, and B. G. Hudson, Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage, Cellular and Molecular Life Sciences, vol. 62, no. 15, pp. 1671-1681, 2005.
30. Y. Mori, T. Kakuta, T. Miyakogawa, et al., Effect of Scavenging circulating reactive carbonyls by oral pyridoxamine in uremic rats on peritoneal dialysis, Therapeutic Apheresis and Dialysis, 2016.